Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD19(B43)-pokeweed antiviral protein immunotoxin selectively inhibited clonogenic RS4;11 cells in vitro, markedly reduced the burden of disseminated leukemia of severe combined immunodeficient mice, and, most importantly, resulted in the long-term survival of treated animals.
|
1370213 |
1992 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that a highly aggressive subclone of murine BCL-1 B-lineage leukemia expresses a single 2.4-kb transcript hybridizing to the human CD19 cDNA probe and reacts strongly with the anti-human CD19 monoclonal antibodies (MoAb) B43, B4, Leu-12, and J3-119.
|
1375109 |
1992 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
|
7678881 |
1993 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In one case a bilineage leukemia with a POEM+/CD 19- and a POEM-/CD 19+ population could be identified by immunoelectron microscopical studies (IEM).
|
7920215 |
1994 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four hematological groups could be distinguished: (i) 13 cases of acute lymphoblastic leukemia (ALL) of B lineage, mostly CD19+; (ii) eight cases of biphenotypic leukemia: CD19+ (most often) ALL but with simultaneous or inducible expression of differentiation marker of monocytic lineage.
|
8426468 |
1993 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The clinicopathological features of these cases were analyzed to determine the influence of age, secondary karyotype abnormalities, and expression of the lymphoid marker CD19 on event free survival, and presence of extramedullary leukemia on overall survival.
|
11426630 |
2000 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data support the hypothesis that the leukemia in TEL/AML1-positive childhood ALL originates in a CD19+ lymphoid progenitor.
|
12091359 |
2002 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
|
12393484 |
2003 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity.
|
15507526 |
2005 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative.
|
15863212 |
2005 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The engineered CD4(+) T cells and CD8(+) T cells both exhibited specific cytotoxicity against CD19(+) leukemia and lymphoma cell lines, as well as against CD19 transfectants, and produced high-levels of antigen-dependent Th1 (but not Th2) cytokines.
|
18227839 |
2008 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
|
18829563 |
2008 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
|
19147788 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28.
|
19238016 |
2009 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In vitro-stimulated NK cells from healthy donors and pediatric leukemia patients were gene modified with CD19 or G(D2)-specific chimeric receptors containing either the T-cell receptor zeta or 2B4 endodomain alone or combined.
|
19638467 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that UCB-19BBzeta and UCB-28BBzeta T cells exhibited more cytotoxicity to CD19(+) leukemia and lymphoma cell lines than UCB-19zeta and UCB-1928zeta, although differences in secretion of interleukin-2 and interferon-gamma by these T cells were not evident.
|
19719389 |
2010 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over-expression of human TCL1, a known CLL oncogene in murine B-cells leads to the development of mature CD19+/CD5+/IgM+ clonal leukemia with a disease phenotype similar to that seen in human CLL.
|
19901553 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD34(+)CD38(-)CD19(+), CD34(+)38(+)CD19(+), and CD34(-)CD38(+)CD19(+) fractions could self-renew and transfer the leukemia, whereas the CD34(-)CD38(+)CD19(+) fraction did not stably propagate in NOD/SCID mice.
|
20028384 |
2010 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this murine model, we identified a new, Rag1-independent leukemia-initiating mechanism originating from a Sca1(+)CD19(+) precursor cell population and showed that Notch1 expression accelerates the cells' self-renewal capacity in vitro.
|
21622646 |
2011 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unexpectedly, a single injection of CD19 RNA CAR T cells reduced disease burden within 1 day after administration, resulting in a significant prolongation of survival in an aggressive leukemia xenograft model.
|
21838572 |
2011 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The observed in vitro and in vivo anti-leukemic potency of the αCD19-AON immunoconjugate provides the first preclinical proof-of-principle that t(1;19)(+) high risk B-lineage ALL can be treated with leukemia-specific biotherapeutic agents that knock-down E2A-PBX1 expression.
|
22990208 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
|
23233573 |
2012 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19(+) leukemia xenografts in mice were reduced with CAR(+)γδ T cells compared with control mice.
|
23295945 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is a clonal expansion of CD5(+)CD19(+) B lymphocytes.
|
23296468 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells.
|
23296936 |
2013 |